NASDAQ:SUPN Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis $32.34 +0.04 (+0.12%) Closing price 04:00 PM EasternExtended Trading$33.25 +0.91 (+2.81%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Supernus Pharmaceuticals Stock (NASDAQ:SUPN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SUPN alerts:Sign Up Key Stats Today's Range$31.99▼$32.6250-Day Range$30.29▼$33.4352-Week Range$25.53▼$40.28Volume296,078 shsAverage Volume481,242 shsMarket Capitalization$1.81 billionP/E Ratio30.22Dividend YieldN/APrice Target$36.00Consensus RatingHold Company OverviewSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.Read More… Supernus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreSUPN MarketRank™: Supernus Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 647th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSupernus Pharmaceuticals has received no research coverage in the past 90 days.Read more about Supernus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-39.50% Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is 30.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is 30.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.11.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Supernus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.89% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-2.35 Percentage of Shares Shorted7.89% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.74 News SentimentSupernus Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Supernus Pharmaceuticals this week, compared to 5 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.80% of the stock of Supernus Pharmaceuticals is held by insiders.Read more about Supernus Pharmaceuticals' insider trading history. Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SUPN Stock News HeadlinesBranded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)June 2 at 5:37 AM | msn.comJay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus PharmaceuticalsMay 29, 2025 | globenewswire.comElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.June 5, 2025 | True Market Insiders (Ad)Supernus to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSupernus Announces Paragraph IV ANDA Filings for Qelbree®May 28, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), 908 Devices (MASS) and Supernus Pharmaceuticals (SUPN)May 24, 2025 | theglobeandmail.comSupernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHDMay 20, 2025 | quiverquant.comSolid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A BusinessMay 13, 2025 | finance.yahoo.comSee More Headlines SUPN Stock Analysis - Frequently Asked Questions How have SUPN shares performed this year? Supernus Pharmaceuticals' stock was trading at $36.16 at the start of the year. Since then, SUPN stock has decreased by 10.6% and is now trading at $32.34. View the best growth stocks for 2025 here. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its quarterly earnings data on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals's revenue was up 14.2% on a year-over-year basis. Read the conference call transcript. Who are Supernus Pharmaceuticals' major shareholders? Top institutional shareholders of Supernus Pharmaceuticals include Vanguard Group Inc. (11.01%), Armistice Capital LLC (9.28%), Stephens Investment Management Group LLC (3.11%) and GW&K Investment Management LLC (2.48%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola and Jonathan Rubin. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY). Company Calendar Last Earnings11/04/2024Today6/05/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SUPN CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees580Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$36.00 Low Stock Price Target$36.00 Potential Upside/Downside+11.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.11 Trailing P/E Ratio30.19 Forward P/E Ratio13.57 P/E GrowthN/ANet Income$1.32 million Net Margins9.16% Pretax Margin11.12% Return on Equity7.79% Return on Assets5.67% Debt Debt-to-Equity RatioN/A Current Ratio2.20 Quick Ratio1.98 Sales & Book Value Annual Sales$668.00 million Price / Sales2.71 Cash Flow$1.48 per share Price / Cash Flow21.83 Book Value$16.87 per share Price / Book1.91Miscellaneous Outstanding Shares55,990,000Free Float50,084,000Market Cap$1.81 billion OptionableOptionable Beta0.74 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:SUPN) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.